Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Rosiglitazone Treatment Reduces Diabetic Neuropathy in STZ treated DBA/2J mice
Authors
Timothy D Wiggin, Matthias Kretzler, Subramaniam Pennathur, Kelli A. Sullivan,
Frank C Brosius, Eva L Feldman
Submitted By
Eva Feldman on 4/4/2008
Status
Published
Journal
Endocrinology
Year
2008
Date Published
10/1/2008
Volume : Pages
149(10) : 4928 - 4937
PubMed Reference
18583417
Abstract
Diabetic Neuropathy (DN) is a common complication of diabetes. Currently, there
is no drug treatment to prevent or slow the development of DN. Rosiglitazone
(Rosi) is a potent insulin sensitizer and may also slow the development of DN by
a mechanism independent of its effect on hyperglycemia. A two by two design was
used to test the effect of Rosi treatment on the development of DN.
Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and
oxidative stress were quantified, and gene expression was profiled using the
Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach
identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice
developed severe hyperglycemia, DN and elevated oxidative stress. Rosi treatment
did not affect hyperglycemia but did reduce oxidative stress and prevented
development of thermal hypoalgesia. Two novel transcription factor binding
modules were identified that may control genes correlated to changes in DN
following Rosi treatment: SP1F_ZBPF and EGRF_EGRF. Rosi treatment reduced
oxidative stress and DN independent of its insulin sensitizing effects. Gene
expression profiling identified two novel targets activated by Rosi treatment.
These targets may be useful in designing drugs with the same efficacy as Rosi in
treating DN but with fewer undesirable effects.
Investigators with authorship
Name
Institution
Frank Brosius
University of Arizona
Eva Feldman
University of Michigan
Matthias Kretzler
University of Michigan
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!